Summary
The clinical significance of radioimmunological determination of Tissue Polypeptide Antigen (TPA) has been studied on patients with breast cancer (n=376), on “normal subjects” (n=92), on benign diseases of the breast as well as on patients with inflammatory diseases (n=98). TPA levels were elevated (120 U/l or higher) in the group with inflammatory diseases in 68% and in the group with breast cancer (stage IV with progression of disease) in 85%. In all other groups (healthy controls, benign diseases of the breast, breast cancer before operation, breast cancer stage I (NED), breast cancer stage II and III (NED), and breast cancer stage IV (PR/CR), TPA was higher only in 5–22%. TPA determinations seem not to be very useful for diagnostic purposes in breast cancer, but it can be regarded as suitable for monitoring proliferative processes in advanced breast cancer. Limitations result from lack of tumor specificty of the proliferation marker TPA. So far, follow-up studies after mastectomy in breast cancer and in patients with advanced breast cancer under chemotherapy have shown that CEA and TPA are concordant. There is no cross reactivity between CEA and TPA. The main component of the labeled tracer has an isoelectric point of 4.4 but there is some impurity in the tracer as it was shown in chromatofocusing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- NED:
-
no evidence of disease
- PR:
-
partial remission
- CR:
-
complete remission
- SDS:
-
sodium dodecylsulfate
References
Andren-Sandberg A, Isacson S (1977) Tissue polypeptide antigen in colorectal carcinoma. In: Clinical application of carcinoembryonic antigen assay. Proceedings of a Symposion, Nice, October. Excerpta Medica, Amsterdam Oxford, pp 139–143
Björklund B, Björklund V (1957) Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique: Presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy 10:153–184
Björklund B, Wiklund B, Lüning B, Andersson K, Kallin E, Björklund V (1980) Radioimmunoassay of TPA, a laboratory test in cancer. Tumor-Diagnostik 1:78–84
Cooper EH, Bowen M, Turner R, Giles GR, Turner RL, Benson EA (1981) CEA: Its contribution to a cascade of biochemical markers in gastrointestinal and breast cancer. In: Uhlenbruck G, Wintzer G (eds) CEA und andere Tumormarker. Tumor-Diagnostik Verlag, Leonberg, pp 128–141
Cowen DM, Searle F, Wards AM, Benson EA, Smiddy FG, Eaves G, Cooper EH (1978) Multivariate biochemical indicators of breast cancer: An evaluation of their potential in routine practice. Eur J Cancer 14:885–893
Holyoke D, Ming Chu T (1979) Tissue polypeptide antigen. In: Herberman RB, McIntire KR (eds) Immunodiagnosis of cancer, part I. Marcel Dekker Inc, New York Basel, pp 513–521
Kjellgren K (1979) The prognostic significance of consecutive determinations of serum tissue polypeptide antigen (TPA) in human breast cancer. In: Lehmann FG (ed) Carcino-Embryonic Proteins, Vol. II. Elsevier/North Holland, pp 607–610
Lötz A, Vogt W, Popp B, Knedel M (1976) Polygonal interpolation, a simple, rapid, and versatile approximation method requiring minimal computing facilities. Computers Biomed. Res 9:21–28
Lüthgens M, Schlegel G (1980) CEA+TPA in clinical tumor diagnostics with special reference to breast cancer. Tumor-Diagnostik 1:72–77
Lüthgens M, Schlegel G (1981) Verlaufskontrolle mit tissue polypeptide antigen und carcinoembryonalem Antigen in der radioonkologischen Nachsorge und Therapie. Tumor-Diagnostik 2:179–188
Lüning B, Wiklund B, Redelius P, Björklund B (1980) Biochemical properties of tissue polypeptide antigen. Biochim Biophys Acta 624:90–101
McIntire KR (1979) Use of multiple immunoassays for circulating tumor markers. In: Herberman RB, McIntire KR (eds) Immunodiagnosis of cancer, part I. Marcel Dekker Inc, New York Basel, pp 521–539
Menendez-Botet, CJ, Oettgen HF, Pinsky CM, Schwartz MK (1978) A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms. Clin Chem 24:868–872
Mross K, Mross B, Wolfrum DI, Rauschecker H (1983) Determination of TPA levels in different cancer types and controls (in preparation)
Nemoto T, Constantine R, Chu TM (1979) Human tissue polypeptide antigen in breast cancer. JNCI 63/6:1347–1350
Oehr P, Hamann D, Klar R, Schlösser T, Winkler C (1980) Serumkonzentrationen von Tissue Polypeptide Antigen und Tennessee-Antigen im Vergleich zu CEA, AFP und β-HCG bei Patienten mit Harnblasen- und Hodentumoren. Nuc Compact 11:223–227
Redelius P, Lüning B, Björklund B (1980) Chemical studies of tissue polypeptide antigen (TPA). II. Partial amino acid sequences of cyanogen bromide fragments of TPA subunit B1. Acta Chem Scand 834:265–273
Pentycross CR (1982) The Tennessee antigen test. An evaluation in cancer and noncancer patients and normal subjects. Br J Cancer 45:223–229
Rozencweig M, Henson J-C (1975) Breast cancer: Prognostic factors and clinical evaluation. In: Staquet MJ (ed) Cancer therapy: Prognostic factors and criteria of response. Raven, New York, pp 139–183
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mross, K., Mross, B., Wolfrum, D.I. et al. Determination of TPA levels in breast cancer and controls. Klin Wochenschr 61, 461–468 (1983). https://doi.org/10.1007/BF02664334
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02664334